Active, not recruitingPhase 2NCT05303792
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Studying Lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Marlise R. Luskin, MD, MSCEDana-Farber Cancer Institute
- Intervention
- Cyclophosphamide(drug)
- Enrollment
- 68 target
- Eligibility
- 50 years · All sexes
- Timeline
- 2023 – 2029
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- Yale University, New Haven, Connecticut, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
- Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States
- Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States
- Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho, United States
- Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
- Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States
- Northwestern University, Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05303792 on ClinicalTrials.govOther trials for Lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07511426U96-CAR-T-Cells For R/R B-ALLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07316010Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell LymphomaM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07372352Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1, PHASE2NCT07575919Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALLLiping Dou
- ACTIVE NOT RECRUITINGPHASE1NCT07198087A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT07140016A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Astellas Pharma Global Development, Inc.
- RECRUITINGNANCT07191431A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）Ruijin Hospital
- RECRUITINGPHASE1, PHASE2NCT07018752A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasThe Lymphoma Academic Research Organisation